International legal practice Osborne Clarke has advised Actavis UK Limited and Actavis Ireland Limited on its £603m divestment by Teva Pharmaceutical Industries Ltd (“Teva”) to Intas Pharmaceuticals Ltd (“Intas”).
The transaction is part of the European Commission’s anti-trust divestiture requirements arising from global pharmaceutical company Teva’s acquisition of Allergan’s generics business, which closed in August 2016.
Intas, the India-headquartered global pharmaceutical company, acquires Actavis UK Limited and Actavis Ireland for £603m through a share purchase agreement. The deal signed on 5 October 2016 and closed on 9 January 2017, having obtained approval from the European Commission.
The Osborne Clarke team that advised Actavis UK and Actavis Ireland was led by Partner Janita Good, who was assisted by Associate Samantha Peacock.
Earlier this year, the team also advised Accelovance Inc on its multimarket agreement to acquire THERAMetrics CRO operations.
